vs
EXACT SCIENCES CORP（EXAS）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是RBC Bearings INC的1.9倍（$878.4M vs $461.6M），RBC Bearings INC净利率更高（14.6% vs -9.8%，领先24.4%），EXACT SCIENCES CORP同比增速更快（23.1% vs 17.0%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $99.1M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 5.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
EXAS vs RBC — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$461.6M
营收增速更快
EXAS
高出6.1%
17.0%
净利率更高
RBC
高出24.4%
-9.8%
自由现金流更多
EXAS
多$21.3M
$99.1M
两年增速更快
EXAS
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $461.6M |
| 净利润 | $-86.0M | $67.4M |
| 毛利率 | 70.1% | 44.3% |
| 营业利润率 | -9.4% | 22.3% |
| 净利率 | -9.8% | 14.6% |
| 营收同比 | 23.1% | 17.0% |
| 净利润同比 | 90.1% | 16.4% |
| 每股收益（稀释后） | $-0.45 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRBC
| Q4 25 | $878.4M | $461.6M | ||
| Q3 25 | $850.7M | $455.3M | ||
| Q2 25 | $811.1M | $436.0M | ||
| Q1 25 | $706.8M | $437.7M | ||
| Q4 24 | $713.4M | $394.4M | ||
| Q3 24 | $708.7M | $397.9M | ||
| Q2 24 | $699.3M | $406.3M | ||
| Q1 24 | $637.5M | $413.7M |
净利润EXASRBC
| Q4 25 | $-86.0M | $67.4M | ||
| Q3 25 | $-19.6M | $60.0M | ||
| Q2 25 | $-1.2M | $68.5M | ||
| Q1 25 | $-101.2M | $72.7M | ||
| Q4 24 | $-864.6M | $57.9M | ||
| Q3 24 | $-38.2M | $54.2M | ||
| Q2 24 | $-15.8M | $61.4M | ||
| Q1 24 | $-110.2M | — |
毛利率EXASRBC
| Q4 25 | 70.1% | 44.3% | ||
| Q3 25 | 68.6% | 44.1% | ||
| Q2 25 | 69.3% | 44.8% | ||
| Q1 25 | 70.8% | 44.2% | ||
| Q4 24 | 69.0% | 44.3% | ||
| Q3 24 | 69.4% | 43.7% | ||
| Q2 24 | 69.8% | 45.3% | ||
| Q1 24 | 70.0% | 43.1% |
营业利润率EXASRBC
| Q4 25 | -9.4% | 22.3% | ||
| Q3 25 | -3.0% | 21.5% | ||
| Q2 25 | -0.3% | 23.2% | ||
| Q1 25 | -13.6% | 23.0% | ||
| Q4 24 | -122.8% | 21.7% | ||
| Q3 24 | -5.6% | 21.6% | ||
| Q2 24 | -3.8% | 24.0% | ||
| Q1 24 | -16.7% | 22.8% |
净利率EXASRBC
| Q4 25 | -9.8% | 14.6% | ||
| Q3 25 | -2.3% | 13.2% | ||
| Q2 25 | -0.1% | 15.7% | ||
| Q1 25 | -14.3% | 16.6% | ||
| Q4 24 | -121.2% | 14.7% | ||
| Q3 24 | -5.4% | 13.6% | ||
| Q2 24 | -2.3% | 15.1% | ||
| Q1 24 | -17.3% | — |
每股收益（稀释后）EXASRBC
| Q4 25 | $-0.45 | $2.13 | ||
| Q3 25 | $-0.10 | $1.90 | ||
| Q2 25 | $-0.01 | $2.17 | ||
| Q1 25 | $-0.54 | $2.33 | ||
| Q4 24 | $-4.69 | $1.82 | ||
| Q3 24 | $-0.21 | $1.65 | ||
| Q2 24 | $-0.09 | $1.90 | ||
| Q1 24 | $-0.60 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $107.6M |
| 总债务越低越好 | — | $990.2M |
| 股东权益账面价值 | $2.4B | $3.3B |
| 总资产 | $5.9B | $5.1B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资EXASRBC
| Q4 25 | $964.7M | $107.6M | ||
| Q3 25 | $1.0B | $91.2M | ||
| Q2 25 | $858.4M | $132.9M | ||
| Q1 25 | $786.2M | $36.8M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | $76.8M | ||
| Q1 24 | $652.1M | $63.5M |
总债务EXASRBC
| Q4 25 | — | $990.2M | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $915.6M | ||
| Q1 25 | — | $920.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2B |
股东权益EXASRBC
| Q4 25 | $2.4B | $3.3B | ||
| Q3 25 | $2.5B | $3.2B | ||
| Q2 25 | $2.5B | $3.1B | ||
| Q1 25 | $2.4B | $3.0B | ||
| Q4 24 | $2.4B | $2.9B | ||
| Q3 24 | $3.2B | $2.9B | ||
| Q2 24 | $3.2B | $2.8B | ||
| Q1 24 | $3.1B | $2.8B |
总资产EXASRBC
| Q4 25 | $5.9B | $5.1B | ||
| Q3 25 | $5.9B | $5.1B | ||
| Q2 25 | $5.8B | $4.8B | ||
| Q1 25 | $5.7B | $4.7B | ||
| Q4 24 | $5.9B | $4.7B | ||
| Q3 24 | $6.7B | $4.7B | ||
| Q2 24 | $6.7B | $4.7B | ||
| Q1 24 | $6.4B | $4.7B |
负债/权益比EXASRBC
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $99.1M |
| 自由现金流率自由现金流/营收 | 13.7% | 21.5% |
| 资本支出强度资本支出/营收 | 3.6% | 5.0% |
| 现金转化率经营现金流/净利润 | — | 1.81× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRBC
| Q4 25 | $151.7M | $122.1M | ||
| Q3 25 | $219.9M | $88.4M | ||
| Q2 25 | $89.0M | $120.0M | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | $84.0M | ||
| Q3 24 | $138.7M | — | ||
| Q2 24 | $107.1M | $97.4M | ||
| Q1 24 | $-82.3M | — |
自由现金流EXASRBC
| Q4 25 | $120.4M | $99.1M | ||
| Q3 25 | $190.0M | $71.7M | ||
| Q2 25 | $46.7M | $104.3M | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | $73.6M | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | $88.4M | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASRBC
| Q4 25 | 13.7% | 21.5% | ||
| Q3 25 | 22.3% | 15.7% | ||
| Q2 25 | 5.8% | 23.9% | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | 18.7% | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | 21.8% | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASRBC
| Q4 25 | 3.6% | 5.0% | ||
| Q3 25 | 3.5% | 3.7% | ||
| Q2 25 | 5.2% | 3.6% | ||
| Q1 25 | 4.4% | 3.2% | ||
| Q4 24 | 5.1% | 2.6% | ||
| Q3 24 | 3.7% | 4.1% | ||
| Q2 24 | 5.1% | 2.2% | ||
| Q1 24 | 5.9% | — |
现金转化率EXASRBC
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 1.75× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.45× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.59× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
